Excitation-contraction (EC) coupling in skeletal muscle depends upon trafficking of Ca V 1.1, the principal subunit of the dihydropyridine receptor (DHPR) (L-type Ca 2+ channel), to plasma membrane regions at which the DHPRs interact with type 1 ryanodine receptors (RyR1) in the sarcoplasmic reticulum. A distinctive feature of this trafficking is that Ca V 1.1 expresses poorly or not at all in mammalian cells that are not of muscle origin (e.g., tsA201 cells), in which all of the other nine Ca V isoforms have been successfully expressed. Here, we tested whether plasma membrane trafficking of Ca V 1.1 in tsA201 cells is promoted by the adapter protein Stac3, because recent work has shown that genetic deletion of Stac3 in skeletal muscle causes the loss of EC coupling. Using fluorescently tagged constructs, we found that Stac3 and Ca V 1.1 traffic together to the tsA201 plasma membrane, whereas Ca V 1.1 is retained intracellularly when Stac3 is absent. Moreover, L-type Ca 2+ channel function in tsA201 cells coexpressing Stac3 and Ca V 1.1 is quantitatively similar to that in myotubes, despite the absence of RyR1. Although Stac3 is not required for surface expression of Ca V 1.2, the principle subunit of the cardiac/brain L-type Ca 2+ channel, Stac3 does bind to Ca V 1.2 and, as a result, greatly slows the rate of current inactivation, with Stac2 acting similarly. Overall, these results indicate that Stac3 is an essential chaperone of Ca V 1.1 in skeletal muscle and that in the brain, Stac2 and Stac3 may significantly modulate Ca V 1.2 function.
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Stac adaptor protein | L-type Ca 2+ channel | excitation-contraction coupling V oltage-gated calcium channels serve to couple membrane electrical activity to various downstream signaling cascades, whose properties are strongly influenced by the spatial interrelationships between the calcium channels, effector proteins, and cellular organelles that comprise these signaling pathways. For example, in skeletal muscle the link between muscle excitation and contraction [excitation-contraction (EC) coupling] depends upon triadic or dyadic junctions between the plasma membrane and the sarcoplasmic reticulum (SR), with L-type Ca 2+ channels (dihydropyridine receptors, DHPRs) and type 1 ryanodine receptors (RyR1) localized in junctional domains of the plasma membrane and the SR, respectively. The DHPRs, which contain Ca V 1.1 as their principal subunit, are arranged into groups of four ("tetrads"), evidently as a consequence of yet-to-be identified, physical links between the DHPRs and the four homomeric subunits of RyR1 (1, 2) . These links are thought to be necessary for the bidirectional functional interactions between the DHPR and RyR1. In particular, the DHPR is thought to be conformationally coupled to RyR1 with the result that movements of the Ca V 1.1 S4 helices in response to depolarization of the plasma membrane cause RyR1 to release Ca 2+ from the SR. In addition to this orthograde signal, which is necessary for EC coupling, there is also a retrograde signal whereby the association with RyR1 causes the L-type Ca 2+ current via Ca V 1.1 to be larger and to activate more rapidly. Thus, Ca 2+ currents are substantially reduced in size in dyspedic myotubes genetically null for RyR1 (3, 4) .
Given the structural and functional interactions between Ca V 1.1-containing DHPRs and RyR1, it would seem necessary that the trafficking of Ca V 1.1 to the plasma membrane be precisely regulated. As for other high-voltage activated Ca 2+ channels, the auxiliary β-subunit is important for membrane trafficking (5, 6) . However, it is clear that an additional factor(s) is also crucial. Specifically, Ca V 1.1 expresses poorly (7) or not at all in mammalian cells that are not of muscle origin (e.g., tsA201 cells), whereas the closely related cardiac/neuronal L-type Ca 2+ channel, Ca V 1.2, is readily expressed in such cells (8) (9) (10) . The absence of RyR1 seems insufficient to account for the difficulty of expressing Ca V 1.1 in tsA201 cells because Ca V 1.1 expresses well in dyspedic myotubes, albeit producing less current per channel (3). Here we explored the hypothesis that the adaptor protein Stac3 is important for membrane trafficking of Ca V 1.1. Stac3 is one of three isoforms of the Stac family of adaptor proteins, so named because they contain src homology 3 (SH3) and cysteine-rich domains. Based on quantitative PCR of adult mice, transcripts for Stac3 are found at high levels in skeletal muscle and at low levels in the cerebellum, forebrain, and eye, whereas transcripts for Stac2 are found in these same, three, neuronally rich regions at levels comparable to those of Stac3 in skeletal muscle (11) . Transcripts for Stac1 (often designated simply as Stac) are present in cerebellum, fore-/midbrain, and eye (at levels 1/10th or less those of Stac2) and also present in the bladder and adrenal gland (11) . In skeletal muscle, the absence of Stac3 causes the failure of EC coupling in both mice (11) and fish (12) . Moreover, Stac3 appears to interact with Ca V 1.1 based on both localization at triad junctions (11, 12) and coimmunoprecipitation (12) . Our results now indicate that Stac3 is a chaperone protein that binds directly to Ca V 1.1 and is necessary for its plasma membrane expression. Stac3 and Stac2 also bind to Ca V 1.2, which is not required for membrane trafficking Significance Voltage-gated calcium channels are essential for diverse cellular functions. For example, Ca V 1.1 channels trigger skeletal muscle contraction and Ca V 1.2 channels regulate neural gene expression in response to neuronal activity. Thus, it is important to understand the cellular mechanisms that regulate delivery of these channels to the plasma membrane and that govern calcium movements via the membrane-inserted channels. Here we show that the cellular adapter protein "Stac3" participates in both processes. Specifically, Stac3 binds to both Ca V but is functionally important, greatly slowing the inactivation of current. . 1A compares the subcellular distribution of fluorescently tagged Ca V 1.2 and Ca V 1.1, after coexpression in tsA201 cells with the auxiliary β 1a -and α 2 δ-subunits. Ca V 1.2 appeared to be associated with the surface membrane (Fig. 1A, Left) , but Ca V 1.1 had a reticular distribution (Fig. 1A , Right) consistent with retention in the endoplasmic reticulum (ER) (13) . Recently, Stac3 was reported to localize to plasma membrane/SR junctions (triads) in skeletal muscle, to be necessary for skeletal-type EC coupling (not requiring entry of extracellular Ca 2+ ), and to be highly expressed in skeletal muscle but not in cardiac muscle. Thus, we decided to test whether Stac3 would affect the trafficking of Ca V 1.1. Strikingly, the presence of Stac3 caused Ca V 1.1 to associate with the cell surface (Fig. 1B) . To determine whether this surface-associated Ca V 1.1 was actually inserted into the plasma membrane, we used a monoclonal antibody to Ca V 1.1 (14) . This antibody stained intact tsA201 cells coexpressing Ca V 1.1 and Stac3, but not cells expressing only Ca V 1.1 (Fig. S1 ). An obvious feature of cells like those illustrated in Fig. 1B was that Stac3, like Ca V 1.1, was associated with the surface. On the basis of photobleaching analysis, such surface binding was not an intrinsic property of Stac3, but depended instead on Ca V 1.1 also being present (Fig. S2) . Moreover, even with neither β 1a nor α 2 δ, Stac3 appeared able to colocalize at the surface with Ca V 1.1 and to promote the insertion of Ca V 1.1 into the plasma membrane (Fig. S3 ). Taken together, these results strongly suggest that Stac3 binds directly to Ca V 1.1 and that this binding is necessary for efficient delivery of Ca V 1.1-containing DHPRs to the plasma membrane.
Results

Fig
Whole-cell patch clamping was used to test whether Ca V 1.1 was functional after its cotransfection with Stac3 in tsA201 cells. As shown in Fig. 2 , Ca V 1.1 in the absence of Stac3 produced neither Ca 2+ currents nor membrane-bound charge movements (gating currents), whereas, in the presence of Stac3, Ca V 1.1 produced robust Ca 2+ currents and charge movements. Fig. 2 also compares the peak current-voltage and charge-voltage relationships for Ca V 1.1 in tsA201 cells with those of Ca V 1.1 expressed in dysgenic myotubes ("mdg," null for endogenous Ca V 1.1). We had expected that Ca V 1.1 function would differ between the two cell types because RyR1 is present in dysgenic myotubes but not in tsA201 cells and because the absence of RyR1 in dyspedic myotubes (null for endogenous RyR1) has been shown to cause Ca 2+ currents via Ca V 1.1 to activate more rapidly (4) and to be severalfold smaller in relationship to charge movement (G max / Q max ) (3, 4) . However, double-exponential fits (Eq. 3) revealed no significant differences between tsA201 cells and dysgenic myotubes in the rate of Ca 2+ current activation (Fig. 3) . Additionally, based on fits of Boltzmann expressions (Eqs. 1 and 2), there were no significant differences between the two cell types in the magnitude of the ratio G max /Q max (Fig. 3) . Thus, the function of Ca V 1.1 coexpressed with Stac3/β 1a /α 2 δ in tsA201 cells is remarkably similar to that of Ca V 1.1 as part of the DHPR complex in myotubes.
In addition to binding to the DHPR, it has been suggested that Stac3 may also bind to RyR1 and thus serve as a functional link between the two proteins (11, 12) . As a test of this possibility, we determined whether Stac3-YFP had the distribution expected for targeting to plasma membrane/SR junctions, which are present with a punctate distribution in both dyspedic (15, 16) and dysgenic myotubes (17) . Stac3-YFP had a punctate distribution in dyspedic myotubes (Fig. 4A, Left) , which contain DHPRs but lack RyR1. This result is consistent with the apparent interaction between Stac3 and DHPRs in tsA201 cells (Fig. 1B , extended data in Fig.2 ). By contrast, Stac3-YFP had a diffuse distribution in dysgenic myotubes (Fig. 4A, Right) , which contain RyR1 but not Ca V 1.1. This latter result could mean either that Stac3-YFP does not bind to RyR1 or that the RyR1 binding sites are occluded in dysgenic myotubes by endogenous Stac3. Thus, we also tested for an interaction between Stac3-YFP and RyR1 after expression of both in tsA201 cells. Fig. 4B illustrates a cell in which the two proteins were expressed at high levels and shows images obtained before and after bleaching YFP within the indicated region of interest. This bleaching would not have been expected to affect any Stac3-YFP that remained bound to RyR1. Thus, the absence in the postbleach image of YFP fluorescence in regions containing RyR1 argues against a stable interaction between Stac3 and RyR1. This conclusion differs from that drawn from previous work on muscle tissue, in which Stac3 was found to coimmunoprecipitate with RyR1 (12) . It is possible that we failed to detect such an interaction because the C-terminal YFP tag interfered with the binding of Stac3 to RyR1. Alternatively, it may be that the previously described coimmunoprecipitation was a consequence of a ternary complex of Stac3, the DHPR, and RyR1.
As described above, the membrane trafficking of Ca V 1.2 in tsA201 cells does not depend on the presence of Stac proteins (Fig. 1A) . However, low levels of Stac3 transcripts and high levels of Stac2 are present in the cerebellum and fore-/midbrain (11), where Ca V 1.2 is also present (18) . Thus, we tested whether Stac3 and/or Stac2 might interact with Ca V 1.2. As shown in Fig. 5A , both Stac3-YFP and Stac2-YFP colocalized with CFP-Ca V 1.2 at the surface of tsA201 cells. Furthermore, this interaction alters Ca V 1.2 function. Specifically, in addition to causing modest changes in Ca 2+ current magnitude, both Stac2 and Stac3 caused a profound slowing of the rate of inactivation (Fig. 5B) .
Discussion
If, as our results suggest, Stac3 is required for efficient membrane trafficking of Ca V 1.1, then it stands to reason that EC coupling would fail in animals that lack it. However, it seems likely that its continued presence is required for maintaining the EC coupling apparatus in a functional state. In particular, EC coupling is greatly impaired in muscle fibers of Stac3-null zebrafish embryos at 48 h postfertilization (hpf) even though there is a near-normal level of triadic Ca V 1.1 (12) 
The ability to achieve high-level expression of Ca V 1.1 in tsA201 cells provides a new experimental tool that will facilitate the study of skeletal muscle DHPRs without the time and expense involved in maintaining colonies of animals heterozygous for mutations of DHPR subunits. The relative absence of contaminating currents is also an advantage. For example, the ability to study how mutations alter the voltage dependence of Ca V 1.1 charge movements is hampered in dysgenic myotubes by the variable presence of gating currents arising from other ion channels, whereas background gating currents are essentially nonexistent in tsA201 cells (Fig. 2B, Right) . Moreover, experiments on tsA201 cells may provide unexpected insights. For example, it was previously hypothesized that the loss of a "current-enhancing" signal from RyR1 to Ca V 1.1 accounted for the reduced size of Ca 2+ currents in RyR1-null myotubes (3). However, this hypothesis appears to be incompatible with the near equivalence of Ca V 1.1 Ca 2+ currents in tsA201 cells and dysgenic myotubes (Figs. 2 and 3) . Thus, it may be that Ca 2+ currents via Ca V 1.1 are inhibited by other junctional proteins unless RyR1 is present to relieve this inhibition. In principle, this idea and other aspects of DHPR signaling in skeletal muscle Data shown were obtained only from cells in which both peak I-V and Q-V relationships were measured. The G max /Q max ratios for dyspedic and dysgenic myotubes were not corrected for any background charge (unrelated to Ca V 1.1) because this was small in the current experiments: 0.87 ± 0.09 nC/μF, n = 7, measured at +40 mV in naive dysgenic myotubes. could be addressed by using tsA201 cells to manipulate the set of junctional proteins present in addition to Ca V 1.1 and Stac3. Of course, there are many questions about signaling interactions between the DHPR and RyR1 that will continue to require the use of skeletal muscle. However, even those experiments are likely to benefit from insights obtained in experiments on tsA201 cells.
Materials and Methods
Molecular Biology. The construction of the expression plasmids for GFP-tagged, CFP-tagged, YFP-tagged, or unlabeled Ca V 1.1 was described previously (19, 20) . The coding sequence of Ca V 1.2 (21) was inserted "in frame" and downstream of enhanced yellow or cyan fluorescent protein in a mammalian expression vector (pEYFP-C1, pECFP-C1; Clontech) to create YFP-Ca V 1.2 and CFP-Ca V 1.2. The plasmid CFP-RyR1, labeled at its N terminus with enhanced cyan fluorescent protein, was derived from the original GFP-RyR1 plasmid (22, 23) by excising the RyR1 encoding sequence from GFP-RyR1 and inserting it into the multiple-cloning site of ECFP-C1 (Clontech). PCR with the primers [forward (fw)] 5′-GAATTCATGACAGAAAAGGAAGTGGTG-3′ and [reverse (rev)] 5′-GGATCCCAAATCTCCTCCAGGAAGTCG-3′ was used to introduce EcoRI (5′) and BamHI (3′) sites flanking the coding sequence for Stac3 (gene ID 237611; plasmid kindly provided by Eric N. Olson, University of Texas Southwestern Medical Center, Dallas), from which the EcoRI-BamHI fragment was inserted into EYFP-N1 (Clontech) to create Stac3-YFP. To create Stac3-DsRed, the Stac3 fragment from Stac3-YFP was inserted into pDsRed1-N1 (Clontech), using the restriction enzymes HindIII and BamHI. To provide an unlabeled Stac3 construct with a comparable expression level, Stac3-YFP was digested with NdeI and BamHI, and the fragment containing the Stac3 sequence was then ligated to the 3,575-bp fragment of pEYFP-C1 that had been digested with the same enzymes. PCR with the primers (fw) 5′-CTGAGGTACCAACCATGACCGAAATGAGCGAGAAG-3′ and (rev) 5′-GTGGT-ACCTAGATCTCTGCCAAGGAGTCG-3′ was used to introduce KpnI sites and a stop codon flanking the coding sequence for Stac2 (gene ID 217154; OriGene Technologies), from which the KpnI-KpnI fragment was inserted into EYFP-N1. Afterward this construct was digested with NdeI and BamHI, and the fragment containing the Stac2 sequence was then ligated to the 3,575-bp fragment of pEYFP-C1 that had been digested with the same enzymes. Digestion of the plasmid β 1a -YFP (24) Acc65I/BsrGI, followed by self-ligation of the compatible ends, was used to produce the expression vector for unlabeled β 1a . Unlabeled α 2 δ-subunit was kindly provided by William A. Sather (University of Colorado).
Primary Skeletal Muscle Cell Culture and cDNA Microinjection. All procedures involving mice were approved by the University of Colorado DenverAnschutz Medical Campus Institutional Animal Care and Use Committee. Myoblasts were prepared from newborn dysgenic mice, homozygous for absence of Ca V 1.1 (25) , or newborn dyspedic mice, homozygous for absence of RyR1 (26) as described before (27) . For electrophysiological experiments, myoblasts were plated into 35-mm, plastic culture dishes (Falcon) coated with ECL (Millipore). Myoblasts destined for imaging were plated into 35-mm culture dishes with ECL-coated glass-coverslip bottoms (MatTek). Cultures were grown for 4-5 d in a humidified 37°C incubator with 5% (vol/vol) CO 2 in highglucose Dulbecco's modified Eagle medium (DMEM) (Mediatech), supplemented with 10% (vol/vol) FBS and 10% (vol/vol) horse serum (both from HyClone Laboratories). Immunostaining. Transfected tsA201 cells were washed twice with PBS containing 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.47 mM KH 2 PO 4 , pH to 7.4 with HCl, and fixed in paraformaldehyde [4% (vol/vol) in PBS] for 20 min at room temperature. After fixation, the cells were washed three times with PBS and incubated in 10% (vol/vol) goat serum/1% BSA/PBS for 60 min at room temperature. Incubation in mouse Ca V 1.1 subunit primary antibody IIF7 (1:500 diluted in 1% BSA/PBS, kindly provided by Kevin P. Campbell, University of Iowa, Iowa City, IA) was overnight at 4°C, after which the cells were washed three times for 10 min with 1% BSA/PBS. Cells were then incubated in Alexa Fluor 568-labeled secondary antibody (diluted 1:300 in 1% BSA/PBS) for 1h at room temperature, washed with 1% BSA/PBS (3 × 10 min, with gentle agitation), and imaged.
Confocal Microscopy and Photobleaching. Myotubes or tsA201 cells were superfused with Rodent Ringer's solution (146 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM Hepes, pH 7.4, with NaOH) and examined using a Zeiss LSM 710 confocal microscope. Images were obtained as a single optical slice with a 40× [1.3 numerical aperture (NA)] or 63× (1.4 NA) oil immersion objective. Excitation and emission, respectively, were 440 nm (diode laser) and 465-495 nm for CFP, 488 nm (argon laser) and 498-544 nm for GFP, 514 nm (argon laser) and 530-565 nm for YFP, 543 nm (HeNe laser), and either 565-721 nm for DsRed or 596-664 nm for Alexa Fluor 568. Relative to full power output, the excitation was attenuated to ∼4% (440 nm), ∼2% (488 nm and 514 nm), ∼15% (543 nm, DsRed), and ∼3% (543 nm, Alexa Fluor 568). For photobleaching of Stac3-YFP in tsA201 cells, a prebleach image was obtained as described above. Within this image, a smaller region of interest was designated to avoid the cell surface and repeatedly scanned for 15-45 s with nonattenuated 514-nm excitation. About 5-10 s after completion of the bleaching, a postbleach image was then obtained with the same settings as those of the prebleach image.
Measurement of L-Type Ca
2+ Currents and Intramembrane Charge Movements. All experiments were performed at room temperature (∼25°C). Pipettes (∼2.0 MΩ) were fabricated from borosilicate glass and were filled with internal solution, which consisted of 140 mM Cs-aspartate, 10 mM Cs 2 -EGTA, 5 mM MgCl 2 , and 10 mM Hepes, pH 7.4, with CsOH. The bath solution contained 145 mM tetraethylammonium-Cl, 10 mM CaCl 2 , and 10 mM Hepes, pH 7.4, with NaOH. For electrophysiological experiments on (gray symbols, +20 mV, n = 11) and YFP-Ca V 1.2 with either Stac3 (black symbols, +30 mV, n = 9) or Stac2 (white symbols, +20 mV, n = 10). myotubes, 0.003 mM tetrodotoxin (TTX) and 0.1 mM N-benzyl-p-toluene sulphonamide (BTS) were added to the bath solution. To isolate L-type currents in myotubes, voltage was stepped from the holding potential (−80 mV) to −20 mV for 1 s to inactivate endogenous T-type current. For measurement of intramembrane charge movements attributable to Ca V 1.1, 0.1 M LaCl 3 and 0.5 M CdCl 2 were added to the bath solution and a prepulse protocol (28) was used to inactivate T-type Ca 2+ channels and sodium channels. Electronic compensation was used to reduce the effective series resistance to <5 MΩ (time constant <400 μs). Linear components of leak and capacitive current were corrected with −P/4 online subtraction protocols. Filtering was at 2-5 kHz and digitization was either at 10 kHz (L-type currents) or at 25 kHz (charge movements). Cell capacitance was determined by integration of a transient elicited by stepping from the holding potential (−80 mV) to −70 mV, using Clampex 8.2 (Molecular Devices), and was used to normalize charge movements (nC/μF) and ionic currents (pA/pF). Peak current-voltage (I-V) curves were fitted according to
where I is the peal current for the test potential V, V rev is the reversal potential, G max is the maximum Ca 2+ channel conductance, V 1/2 is the halfmaximal activation potential, and k G is the slope factor. Plots of the integral of the ON transient (Q on ) of intramembrane charge movement as a function of test potential (V) were fitted according to
where Q max is the maximal Q on , V Q is the potential causing movement of half the maximal charge, and k Q is a slope parameter. The activation phase of macroscopic ionic currents was fitted as described in ref. 4 , using the exponential function IðtÞ = A fast exp −t τ fast ! + A slow exp −t τ slow ! + C, [3] where I(t) is the current at time t after the depolarization, A fast and A slow are the steady-state current amplitudes of each component with their respective time constants of activation (τ fast and τ slow ), and C represents the peak current. Fractional inactivation of current in 150 ms (R 150 ) was determined by dividing the peak current into the current 150 ms after the peak.
Analysis. Figures were made using the software program SigmaPlot (version 11.0; SSPS). All data are presented as mean ± SEM. Statistical comparisons were made by one-way ANOVA.
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